UroGen Pharma Ltd. (URGN)
URGN Stock Price Chart
Explore UroGen Pharma Ltd. interactive price chart. Choose custom timeframes to analyze URGN price movements and trends.
URGN Company Profile
Discover essential business fundamentals and corporate details for UroGen Pharma Ltd. (URGN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
4 May 2017
Employees
234.00
Website
https://www.urogen.comCEO
Elizabeth A. Barrett
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
URGN Financial Timeline
Browse a chronological timeline of UroGen Pharma Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$0.66, while revenue estimate is $34.71M.
Earnings released on 7 Aug 2025
EPS came in at -$1.05 falling short of the estimated -$0.82 by -28.05%, while revenue for the quarter reached $24.22M , missing expectations by -27.87%.
Earnings released on 12 May 2025
EPS came in at -$0.92 falling short of the estimated -$0.83 by -10.84%, while revenue for the quarter reached $20.25M , missing expectations by -12.93%.
Earnings released on 10 Mar 2025
EPS came in at -$0.80 falling short of the estimated -$0.69 by -15.94%, while revenue for the quarter reached $24.57M , beating expectations by +5.24%.
Earnings released on 6 Nov 2024
EPS came in at -$0.55 surpassing the estimated -$0.84 by +34.52%, while revenue for the quarter reached $25.20M , missing expectations by -3.56%.
Earnings released on 13 Aug 2024
EPS came in at -$0.91 falling short of the estimated -$0.82 by -10.98%, while revenue for the quarter reached $21.85M , missing expectations by -8.81%.
Earnings released on 13 May 2024
EPS came in at -$0.97 falling short of the estimated -$0.93 by -4.30%, while revenue for the quarter reached $18.78M , missing expectations by -12.16%.
Earnings released on 14 Mar 2024
EPS came in at -$0.72 falling short of the estimated -$0.67 by -7.46%, while revenue for the quarter reached $23.53M , beating expectations by +4.25%.
Earnings released on 14 Nov 2023
EPS came in at -$0.68 surpassing the estimated -$0.89 by +23.60%, while revenue for the quarter reached $20.85M , missing expectations by -7.61%.
Earnings released on 10 Aug 2023
EPS came in at -$1.03 surpassing the estimated -$1.13 by +8.85%, while revenue for the quarter reached $21.14M , beating expectations by +5.06%.
Earnings released on 11 May 2023
EPS came in at -$1.30 surpassing the estimated -$1.39 by +6.47%, while revenue for the quarter reached $17.19M , beating expectations by +0.07%.
Earnings released on 16 Mar 2023
EPS came in at -$1.22 falling short of the estimated -$1.12 by -8.93%, while revenue for the quarter reached $18.09M , missing expectations by -2.26%.
Earnings released on 10 Nov 2022
EPS came in at -$1.13 surpassing the estimated -$1.22 by +7.38%, while revenue for the quarter reached $16.10M , missing expectations by -20.10%.
Earnings released on 11 Aug 2022
EPS came in at -$1.18 surpassing the estimated -$1.33 by +11.28%, while revenue for the quarter reached $16.60M , missing expectations by -3.60%.
Earnings released on 10 May 2022
EPS came in at -$1.25 surpassing the estimated -$1.36 by +8.09%, while revenue for the quarter reached $13.56M , missing expectations by -10.60%.
Earnings released on 21 Mar 2022
EPS came in at -$1.27 falling short of the estimated -$1.18 by -7.63%, while revenue for the quarter reached $16.17M , missing expectations by -0.43%.
Earnings released on 15 Nov 2021
EPS came in at -$1.35 falling short of the estimated -$1.26 by -7.14%, while revenue for the quarter reached $11.35M , missing expectations by -26.39%.
Earnings released on 4 Aug 2021
EPS came in at -$1.17 falling short of the estimated -$1.10 by -6.36%, while revenue for the quarter reached $13.03M , meeting expectations.
Earnings released on 13 May 2021
EPS came in at -$1.17 surpassing the estimated -$1.26 by +7.14%, while revenue for the quarter reached $7.49M , missing expectations by -16.83%.
Earnings released on 18 Mar 2021
EPS came in at -$1.38 falling short of the estimated -$1.31 by -5.34%, while revenue for the quarter reached $7.97M , missing expectations by -11.49%.
Earnings released on 9 Nov 2020
EPS came in at -$1.31 surpassing the estimated -$1.47 by +10.88%, while revenue for the quarter reached $3.46M .
URGN Stock Performance
Access detailed URGN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.